Everett Harris & Co. CA Grows Holdings in Amgen Inc. (NASDAQ:AMGN)

Everett Harris & Co. CA grew its stake in Amgen Inc. (NASDAQ:AMGN) by 3.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 22,549 shares of the medical research company’s stock after buying an additional 650 shares during the period. Everett Harris & Co. CA’s holdings in Amgen were worth $6,495,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Fuller & Thaler Asset Management Inc. lifted its holdings in shares of Amgen by 1.7% in the 3rd quarter. Fuller & Thaler Asset Management Inc. now owns 11,658 shares of the medical research company’s stock worth $3,133,000 after acquiring an additional 193 shares during the last quarter. Diversified Trust Co lifted its holdings in shares of Amgen by 76.8% in the 4th quarter. Diversified Trust Co now owns 37,695 shares of the medical research company’s stock worth $10,857,000 after acquiring an additional 16,376 shares during the last quarter. Nicolet Advisory Services LLC lifted its holdings in shares of Amgen by 4.4% in the 3rd quarter. Nicolet Advisory Services LLC now owns 2,805 shares of the medical research company’s stock worth $745,000 after acquiring an additional 117 shares during the last quarter. Platform Technology Partners raised its holdings in Amgen by 7.4% during the 3rd quarter. Platform Technology Partners now owns 5,830 shares of the medical research company’s stock valued at $1,567,000 after buying an additional 402 shares during the last quarter. Finally, Busey Trust CO raised its holdings in Amgen by 1.2% during the 3rd quarter. Busey Trust CO now owns 76,703 shares of the medical research company’s stock valued at $20,615,000 after buying an additional 894 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the stock. Leerink Partnrs lowered shares of Amgen from an “outperform” rating to a “market perform” rating in a report on Wednesday, February 7th. BMO Capital Markets upgraded shares of Amgen from a “market perform” rating to an “outperform” rating and upped their price target for the company from $286.00 to $326.00 in a report on Tuesday, December 19th. Royal Bank of Canada upped their price objective on shares of Amgen from $303.00 to $329.00 and gave the stock an “outperform” rating in a report on Wednesday, February 7th. The Goldman Sachs Group upped their price objective on shares of Amgen from $313.00 to $350.00 and gave the stock a “buy” rating in a report on Wednesday, February 7th. Finally, UBS Group decreased their price objective on shares of Amgen from $315.00 to $314.00 and set a “neutral” rating for the company in a report on Monday, January 29th. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $295.30.

Amgen Stock Performance

Shares of NASDAQ AMGN opened at $284.32 on Friday. The firm’s 50-day moving average price is $290.09 and its 200-day moving average price is $280.70. The company has a quick ratio of 1.13, a current ratio of 1.65 and a debt-to-equity ratio of 10.14. The company has a market cap of $152.37 billion, a PE ratio of 22.76, a PEG ratio of 2.66 and a beta of 0.58. Amgen Inc. has a 52-week low of $211.71 and a 52-week high of $329.72.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, February 6th. The medical research company reported $4.71 earnings per share for the quarter, topping the consensus estimate of $4.66 by $0.05. Amgen had a net margin of 23.83% and a return on equity of 154.27%. The firm had revenue of $8.20 billion for the quarter, compared to analysts’ expectations of $8.13 billion. During the same quarter in the prior year, the business earned $4.09 EPS. The business’s quarterly revenue was up 19.8% on a year-over-year basis. As a group, analysts anticipate that Amgen Inc. will post 19.49 EPS for the current year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 7th. Investors of record on Friday, May 17th will be issued a $2.25 dividend. This represents a $9.00 dividend on an annualized basis and a dividend yield of 3.17%. The ex-dividend date is Thursday, May 16th. Amgen’s dividend payout ratio (DPR) is presently 72.06%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.